
- Volume 0 0
ACCEPTANCE OF GENERICS HOLDS DOWN PART D COSTS
New government data suggestthat American consumersare warming up to genericpharmaceuticals as a keystrategy for holding down theirmedication costs. The data,released by the Centers forMedicare & Medicaid Services(CMS), concluded that genericuse is especially high amongseniors in the new Medicaredrug benefit. According toCMS, cheaper generics accountedfor nearly 60% of thedrugs dispensed to people inMedicare Part D plans duringthe first 9 months of 2006.
Representatives of thenation's pharmacy benefitmanagers quickly took creditfor the growing generic usage,noting that the CMS information"underscores the role ofpharmacy benefit managers(PBMs) in expanding access tolower-cost, clinically provenprescription drugs." In a statementresponding to the newgeneric use figures, officials atthe Pharmaceutical CareManagement Association(PCMA) said that the "highgeneric dispensing rate inMedicare Part D—after only 1year—is a testament to thecollaborative efforts of patients,clinicians, PBMs, andpolicy makers to expandaccess to clinically proven,cost-effective prescriptiondrugs."
Indeed, PCMA said, the"increased generic-drug utilizationis helping to keep PartD premiums and programcosts lower than originallyforecast and is helping to preventseniors from falling intothe ‘doughnut hole'coveragegap."
Articles in this issue
over 18 years ago
Maniaover 18 years ago
Smoking Cessationover 18 years ago
New Drugs of 2006over 18 years ago
compounding HOTLINEover 18 years ago
Prevention and Treatment of Hyperglycemia in Hospitalized Patientsover 18 years ago
Reconsidering the Ban on Ephedra Productsover 18 years ago
Worldwide Prescription Drug Abuseover 18 years ago
RESPy AWARD: Dia Makes a Difference in Pharmacyover 18 years ago
E-prescribing Can Make a Difference for Medicare Part Dover 18 years ago
ncpa SPEAKS OUT: Medicaid Actions, Pharmacy ReactionsNewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.